Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people
Hajira Dambha‐Miller(NIHR Southampton Biomedical Research Centre), Simon J. Griffin(MRC Epidemiology Unit), William Hinton(University of Oxford), Mark Joy(University of Surrey), Christopher R Wilcox(Royal Gwent Hospital), Michael Feher(University of Oxford), Agnieszka Lemańska(University of Surrey), Julia Hippisley‐Cox(Queen Mary University of London), Beth Stuart(Queen Mary University of London), Simon de Lusignan(University of Oxford)
Cited by 7
Related Papers
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
|BMJ|2008|1.5k
Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial
|The Lancet|2013|440
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Physical activity, mental health and well-being of adults during initial COVID-19 containment strategies: A multi-country cross-sectional analysis
|Journal of science and medicine in sport|2020|281